T2 Discussions: Trending Topics Resource hub

This promotional website has been developed, organised and funded by Boehringer Ingelheim.

Prescribing information for the United Kingdom and Republic of Ireland.
Adverse event reporting information can be found at the bottom of the page.

Did you know?

Approximately 45,000 premature deaths in UK every year are due to CKD⁶

Experts are urging for more to be done to:

Help patients recognise the signs of CKD and engage with CKD testing⁷

Support HCPs with the early detection of CKD and identify opportunities for intervention⁸

Proven efficacy vs placebo^1,9

Proven efficacy vs placebo:^1,9 The efficacy and safety of 5 mg linagliptin was evaluated in eight phase III randomised controlled trials. Linagliptin once daily demonstrated clinically significant improvements in glycaemic control vs placebo or comparator.¹

Demonstrated CV and kidney safety profile

Long-term cardiovascular and kidney safety profile of TRAJENTA® has been demonstrated in two cardiovascular outcome trials.^{10⁠–⁠16} As TRAJENTA® is primarily excreted via the bile, it is suitable for a broad range of adults with type 2 diabetes independent of renal function.¹

Unique convenience of one dose, once daily¹

The recommended dose of TRAJENTA® for adult patients with type 2 diabetes is 5 mg once daily, independent of renal and hepatic function, body mass index, age, ethnicity, background type 2 diabetes therapy, and disease duration.^1,16

Sarah Jarvis
Webinar Series Chair

Watch the most recent webinar

Initiated and funded by
Boehringer Ingelheim

PC-GB-110175 V2 | December 2024

^§ Treatment difference of 0.8% in favour of linagliptin for adjusted mean HbA1c reduction at 24 weeks between linagliptin and placebo groups.

CKD: chronic kidney disease; CV: cardiovascular; SmPC: Summary of Product Characteristics.

References:

TRAJENTA^® (linagliptin) Summary of Product Characteristics (SmPC).*
Sitagliptin SmPC.*
Vildagliptin SmPC.*
Saxagliptin SmPC.*
Alogliptin SmPC.**
Kidney Care UK (2024). Key facts about kidneys. Available at: https://kidneycareuk.org/kidney-disease-information/about-kidney-health/facts-about-kidneys/ (accessed March 2025)
Kidney Research UK (2018). Kidney Research UK and Diabetes UK joint statement. Available at: https://www.kidneyresearchuk.org/research/partnerships
collaboration/kidney-research-uk-and-diabetes-uk-joint-statement/ (accessed March 2025)
Kidney Research UK (2024). Chronic kidney disease and prevention: Harnessing the potential of early intervention and disease management. Available at: https://www.kidneyresearchuk.org/wp-content/uploads/2023/03/Kidney-Research-report-on-prevention-and-early-detection.pdf (accessed March 2025)

Del Prato S, et al. J Diab Compl. 2013;27:274–279.
Rosenstock J, et al. Cardiovasc Diabetol. 2018;17:39.
Rosenstock J, et al. JAMA. 2019;321:69–79.
Cooper M, et al. Diabetes Obes Metab. 2020;22:1062–73.
Marx N, et al. Diab Vasc Res. 2015;12:164–74.
Rosenstock J, et al. JAMA. 2019;322:1155–66.
Espeland MA, et al. Diabetes Obes Metab. 2021;23:569–80.
Lajara R, et al. Clin Ther. 2014:36:1595–605.

*Summary of Product Characteristics for Trajenta, sitagliptin, vildagliptin and saxagliptin are available at: https://www.medicines.org.uk (UK) and https://www.medicines.ie/ (ROI).

**Summary of Product Characteristics for alogliptin is available at: https://www.medicines.org.uk (UK).

Prescribing information for the United Kingdom and Republic of Ireland.

Trajenta is indicated in adults with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control as:
• monotherapy when metformin is inappropriate due to intolerance, or contraindicated due to renal impairment
• in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control

The content has been reviewed and approved by the sponsoring company prior to its publication. Editorial support for this website has been provided by
OmniaMed Communications.

Adverse events should be reported. Reporting forms and information can be found at https://www.mhra.gov.uk/yellowcard (UK) or https://www.hpra.ie/homepage/about-us/report-an-issue (IRE). Adverse events should also be reported to Boehringer Ingelheim Drug Safety on 0800 328 1627 (freephone) (UK) or 01 2913960 (IRE), Fax: +44 1344 742661, or by e-mail: [email protected].

PC-GB-106627 V10 | March 2025

Did you know?

Approximately 45,000 premature deaths in UK every year are due to CKD6 Experts are urging for more to be done to: Help patients recognise the signs of CKD and engage with CKD testing7 Support HCPs with the early detection of CKD and identify opportunities for intervention8

Sarah JarvisWebinar Series Chair

You are leaving this site.

Approximately 45,000 premature deaths in UK every year are due to CKD⁶

Experts are urging for more to be done to:

Help patients recognise the signs of CKD and engage with CKD testing⁷

Support HCPs with the early detection of CKD and identify opportunities for intervention⁸

Sarah Jarvis
Webinar Series Chair